edgeTI (OTCQB: UNFYF): CEO on the 3 reasons to watch. Real need, TRL 9 tech, fast growth.
#DefenseTech #RedChip
#DefenseTech #RedChip
0
0
0
51
BioVie ($BIVI): New Biomarker Data at NIH Workshop Help Explain Who Benefits Most from Bezisterim in Long COVID
BioVie presented new biomarker findings from its Phase 2 ADDRESS-LC trial at the NIH’s RECOVER-TLC workshop, the initiative created to speed the development of Long COVID treatments. Analyzing 380 plasma biomarkers, BioVie identified two distinct patient groups with different responses to bezisterim. In highly inflamed patients, it showed a large effect on objective cognition (p=0.001). In a less-inflamed group, it was associated with improvements in fatigue and post-exertional malaise. Bezisterim also lowered neuropeptide Y, a biomarker elevated in ME/CFS and Gulf War Syndrome, by about 33%. BioVie says the findings provide a potential biological explanation for its earlier clinical results and could help target future trials to the patients most likely to benefit. More data will be presented this week at the Long COVID International Conference in Nice.
Full press release: redchip.news/3WWntIt
BioVie presented new biomarker findings from its Phase 2 ADDRESS-LC trial at the NIH’s RECOVER-TLC workshop, the initiative created to speed the development of Long COVID treatments. Analyzing 380 plasma biomarkers, BioVie identified two distinct patient groups with different responses to bezisterim. In highly inflamed patients, it showed a large effect on objective cognition (p=0.001). In a less-inflamed group, it was associated with improvements in fatigue and post-exertional malaise. Bezisterim also lowered neuropeptide Y, a biomarker elevated in ME/CFS and Gulf War Syndrome, by about 33%. BioVie says the findings provide a potential biological explanation for its earlier clinical results and could help target future trials to the patients most likely to benefit. More data will be presented this week at the Long COVID International Conference in Nice.
Full press release: redchip.news/3WWntIt
0
0
0
84
📣 Gunnison Copper ($GUNN) Live Investor Webinar: Monday, November 23 at 4:15 PM ET
Permitting is the biggest risk facing new U.S. mining projects, and Gunnison Copper’s flagship deposit in Southern Arizona is already permitted from past mining. The company also has a producing ch it built quickly with a major partner. Mark your calendar to hear CEO Craig Hallworth explain how the company plans to move its flagship project toward production on an accelerated timeline.
🔍 Why investors are watching:
One of the largest undeveloped oxide copper resources in the U.S.
The flagship deposit was mined before, so it’s already permitted and needs only amendments
Located in Southern Arizona, close to infrastructure
Johnson Camp, a producing mine built for about $200M with partner Rio Tinto
Register now to reserve your spot for the live presentation and Q&A.
🔗 Register here: redchip.news/4C2qrvk
#GUNN #GunnisonCopper #Copper #CopperMining #Arizona #CriticalMinerals #MiningStocks #NYSEAmerican #InvestorWebinar #SmallCapInvesting
Permitting is the biggest risk facing new U.S. mining projects, and Gunnison Copper’s flagship deposit in Southern Arizona is already permitted from past mining. The company also has a producing ch it built quickly with a major partner. Mark your calendar to hear CEO Craig Hallworth explain how the company plans to move its flagship project toward production on an accelerated timeline.
🔍 Why investors are watching:
One of the largest undeveloped oxide copper resources in the U.S.
The flagship deposit was mined before, so it’s already permitted and needs only amendments
Located in Southern Arizona, close to infrastructure
Johnson Camp, a producing mine built for about $200M with partner Rio Tinto
Register now to reserve your spot for the live presentation and Q&A.
🔗 Register here: redchip.news/4C2qrvk
#GUNN #GunnisonCopper #Copper #CopperMining #Arizona #CriticalMinerals #MiningStocks #NYSEAmerican #InvestorWebinar #SmallCapInvesting
0
0
1
110
📣 Two Days Out: 60 Degrees Pharmaceuticals ($SXTP) Live Investor Webinar, Tuesday, November 10 at 4:15 PM ET
If you haven’t registered yet, now is the time. On Tuesday, management will cover both sides of the 60P story: a commercial antimalarial business that is scaling up and rgeting a large market with no approved treatment. It’s a direct chance to ask about the upcoming data and the commercial plan.
🎯 Key catalysts to hear about:
Initial data from three babesiosis clinical studies, expected in late 2026
A regulatory strategy for an FDA submission, to be set after the data
Up to $245M in potential peak annual babesiosis sales, based on initial research estimates
Up to $1.1B in potential cumulative revenue through patent expiration in 2035
Babesiosis appears in about 10% of Lyme disease cases, and its geographic range is expanding
Register now so you can join the live presentation and Q&A.
🔗 Register here: redchip.news/4iA1YV5
#SXTP #60DegreesPharma #Babesiosis #LymeDisease #InfectiousDisease #Biotech #BiotechStocks #NasdaqStocks #InvestorWebinar #SmallCapInvesting
If you haven’t registered yet, now is the time. On Tuesday, management will cover both sides of the 60P story: a commercial antimalarial business that is scaling up and rgeting a large market with no approved treatment. It’s a direct chance to ask about the upcoming data and the commercial plan.
🎯 Key catalysts to hear about:
Initial data from three babesiosis clinical studies, expected in late 2026
A regulatory strategy for an FDA submission, to be set after the data
Up to $245M in potential peak annual babesiosis sales, based on initial research estimates
Up to $1.1B in potential cumulative revenue through patent expiration in 2035
Babesiosis appears in about 10% of Lyme disease cases, and its geographic range is expanding
Register now so you can join the live presentation and Q&A.
🔗 Register here: redchip.news/4iA1YV5
#SXTP #60DegreesPharma #Babesiosis #LymeDisease #InfectiousDisease #Biotech #BiotechStocks #NasdaqStocks #InvestorWebinar #SmallCapInvesting
0
0
0
169
Alliance Entertainment ($AENT): $1.15 Billion in Sales, a $231 Million Market Cap. What Is Wall Street Missing?
Streaming didn’t kill physical media. It turned it into a collectible. Alliance Entertainment’s fiscal 2026 revenue reached $1.15 billion, up 8%, with CDs up 25%, physical movies up 22% and vinyl up 13%. Profitability grew even faster: gross profit rose 15% and adjusted EPS jumped 24% to $0.46. Alliance is also moving beyond wholesale distribution into premium exclusives, proprietary collectibles and authentication. AENT trades at about 9.9 times trailing adjusted earnings, and RedChip’s latest article looks at what it could take for the market to re-rate the stock.
Full article: redchip.news/4BLKwpx
Streaming didn’t kill physical media. It turned it into a collectible. Alliance Entertainment’s fiscal 2026 revenue reached $1.15 billion, up 8%, with CDs up 25%, physical movies up 22% and vinyl up 13%. Profitability grew even faster: gross profit rose 15% and adjusted EPS jumped 24% to $0.46. Alliance is also moving beyond wholesale distribution into premium exclusives, proprietary collectibles and authentication. AENT trades at about 9.9 times trailing adjusted earnings, and RedChip’s latest article looks at what it could take for the market to re-rate the stock.
Full article: redchip.news/4BLKwpx
1
0
0
171
📣 FibroBiologics (NASDAQ: FBLG) Live Investor Webinar: Thursday, November 19 at 4:15 PM ET
FibroBiologics is a clinical-stage biotechnology company developing therapies, and seeking potential cures, for chronic diseases using fibroblasts, the most common cell type in connective l property portfolio spans wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity and cancer. Mark your calendar to hear management discuss the platform and what’s ahead.
🔍 Why investors are watching:
More than 270 U.S. and international patents issued and pending
A newly granted European patent covering fibroblasts engineered to carry cancer-fighting agents, including oncolytic viruses, directly to tumors
Preclinical data presented at NASS 2026 showing its chondrocyte spheroids preserved disc height better than any other fibroblast-based approach tested
A pipeline spanning multiple chronic disease indications from one cell-based platform
Based in Houston and led by Founder and CEO Pete O’Heeron
Register now to reserve your spot for the live presentation and Q&A.
🔗 Register here: redchip.news/4fchsh2
#FBLG #FibroBiologics #CellTherapy #Fibroblasts #RegenerativeMedicine #WoundHealing #Biotech #NasdaqStocks #InvestorWebinar #SmallCapInvesting
FibroBiologics is a clinical-stage biotechnology company developing therapies, and seeking potential cures, for chronic diseases using fibroblasts, the most common cell type in connective l property portfolio spans wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity and cancer. Mark your calendar to hear management discuss the platform and what’s ahead.
🔍 Why investors are watching:
More than 270 U.S. and international patents issued and pending
A newly granted European patent covering fibroblasts engineered to carry cancer-fighting agents, including oncolytic viruses, directly to tumors
Preclinical data presented at NASS 2026 showing its chondrocyte spheroids preserved disc height better than any other fibroblast-based approach tested
A pipeline spanning multiple chronic disease indications from one cell-based platform
Based in Houston and led by Founder and CEO Pete O’Heeron
Register now to reserve your spot for the live presentation and Q&A.
🔗 Register here: redchip.news/4fchsh2
#FBLG #FibroBiologics #CellTherapy #Fibroblasts #RegenerativeMedicine #WoundHealing #Biotech #NasdaqStocks #InvestorWebinar #SmallCapInvesting
0
0
0
160
FibroBiologics ($FBLG): Granted European Patent for Using Fibroblasts to Deliver Cancer-Fighting Agents to Tumors
The European Patent Office has granted FibroBiologics a patent covering methods of turning fibroblasts into tumor-targeting delivery vehicles. The fibroblasts are modified to home in on cancer cells and loaded with tumor inhibitory agents such as oncolytic viruses. In a mouse melanoma model described in the patent, fibroblasts carrying an oncolytic virus significantly inhibited tumor growth, while the virus given alone, even at high doses, did not. The patent adds to FibroBiologics’ portfolio of more than 270 issued and pending patents.
Full press release: redchip.news/4z4YSyJ
The European Patent Office has granted FibroBiologics a patent covering methods of turning fibroblasts into tumor-targeting delivery vehicles. The fibroblasts are modified to home in on cancer cells and loaded with tumor inhibitory agents such as oncolytic viruses. In a mouse melanoma model described in the patent, fibroblasts carrying an oncolytic virus significantly inhibited tumor growth, while the virus given alone, even at high doses, did not. The patent adds to FibroBiologics’ portfolio of more than 270 issued and pending patents.
Full press release: redchip.news/4z4YSyJ
0
0
0
167
📣 60 Degrees Pharmaceuticals ($SXTP) Live Investor Webinar: Next Tuesday, November 10 at 4:15 PM ET
60 Degrees Pharmaceuticals markets ARAKODA® (tafenoquine), an FDA-approved antimalarial, and is advancing it into babesiosis, a growing tick-borne infection with no FDA-approved a from three babesiosis clinical studies is expected in late 2026, and the company plans to set its FDA regulatory strategy after that. Mark your calendar to hear management discuss the commercial business and the clinical path ahead.
🔍 Why investors are watching:
ARAKODA® is an FDA-approved, long-acting antimalarial co-developed with the U.S. Army
More than 1,100 patient exposures across 8+ published trials
No FDA-approved treatments currently exist for babesiosis
Three clinical studies in babesiosis are expected to yield initial data in late 2026
An initial estimate of up to 380,000 addressable U.S. babesiosis patients each year
Register now to reserve your spot for the live presentation and Q&A.
🔗 Register here: redchip.news/4iA1YV5
#SXTP #60DegreesPharma #Babesiosis #LymeDisease #InfectiousDisease #Biotech #BiotechStocks #NasdaqStocks #InvestorWebinar #SmallCapInvesting #RedChip
60 Degrees Pharmaceuticals markets ARAKODA® (tafenoquine), an FDA-approved antimalarial, and is advancing it into babesiosis, a growing tick-borne infection with no FDA-approved a from three babesiosis clinical studies is expected in late 2026, and the company plans to set its FDA regulatory strategy after that. Mark your calendar to hear management discuss the commercial business and the clinical path ahead.
🔍 Why investors are watching:
ARAKODA® is an FDA-approved, long-acting antimalarial co-developed with the U.S. Army
More than 1,100 patient exposures across 8+ published trials
No FDA-approved treatments currently exist for babesiosis
Three clinical studies in babesiosis are expected to yield initial data in late 2026
An initial estimate of up to 380,000 addressable U.S. babesiosis patients each year
Register now to reserve your spot for the live presentation and Q&A.
🔗 Register here: redchip.news/4iA1YV5
#SXTP #60DegreesPharma #Babesiosis #LymeDisease #InfectiousDisease #Biotech #BiotechStocks #NasdaqStocks #InvestorWebinar #SmallCapInvesting #RedChip
0
0
0
155
Bimergen Energy ($BESS): Noble Capital Markets Initiates Coverage with $6 Price Target
Noble Capital Markets has initiated company-sponsored equity research coverage on Bimergen Energy (NYSE-A: BESS) with an Outperform rating and a $6.00 price target. The report highlights Bimergen’s 23 battery storage projects totaling nearly 2 GW, its ability to monetize projects while retaining ownership interests, and the potential for recurring revenue as projects become operational. Bimergen is now covered by four firms, with price targets ranging from $6.00 to $10.00 and a median price target of $9.50. All four research reports are available on Bimergen’s website.
Full press release: redchip.news/4iXO6VX
Noble Capital Markets has initiated company-sponsored equity research coverage on Bimergen Energy (NYSE-A: BESS) with an Outperform rating and a $6.00 price target. The report highlights Bimergen’s 23 battery storage projects totaling nearly 2 GW, its ability to monetize projects while retaining ownership interests, and the potential for recurring revenue as projects become operational. Bimergen is now covered by four firms, with price targets ranging from $6.00 to $10.00 and a median price target of $9.50. All four research reports are available on Bimergen’s website.
Full press release: redchip.news/4iXO6VX
0
0
0
148
🚨 TODAY: Hawkeye Digital (OTCQB: HWKE) Live Investor Webinar at 4:15 PM ET
The Hawkeye Digital investor webinar is today. This afternoon, management will present a platform built to profit from the growth of the digital asset ecosystem without depending on token prices. Bring erchant banking pipeline, private equity targets and the uplisting plan.
📋 What’s on the table today:
An integrated merchant banking and private equity model focused on digital assets
President David Wachsman’s advisory relationships with Ripple, Circle, Tether, Binance, OKX, Solana Foundation and ConsenSys
A private equity strategy targeting mature, cash-generating digital asset businesses
ThinkEquity serves as financial advisor and is an investor in the company
A clear path toward a national exchange uplisting
Register now to join the live presentation this afternoon.
🔗 Register here: redchip.news/4Bh8Uix
#HWKE #HawkeyeDigital #DigitalAssets #Blockchain #Crypto #Tokenization #PrivateEquity #OTCQB #InvestorWebinar #SmallCapInvesting
The Hawkeye Digital investor webinar is today. This afternoon, management will present a platform built to profit from the growth of the digital asset ecosystem without depending on token prices. Bring erchant banking pipeline, private equity targets and the uplisting plan.
📋 What’s on the table today:
An integrated merchant banking and private equity model focused on digital assets
President David Wachsman’s advisory relationships with Ripple, Circle, Tether, Binance, OKX, Solana Foundation and ConsenSys
A private equity strategy targeting mature, cash-generating digital asset businesses
ThinkEquity serves as financial advisor and is an investor in the company
A clear path toward a national exchange uplisting
Register now to join the live presentation this afternoon.
🔗 Register here: redchip.news/4Bh8Uix
#HWKE #HawkeyeDigital #DigitalAssets #Blockchain #Crypto #Tokenization #PrivateEquity #OTCQB #InvestorWebinar #SmallCapInvesting
0
0
1
158
Join Our Investor LIVE Q&A Noble Africa - LIVE NOW x.com/i/broadcasts/2…
0
0
1
139
⏳ Starting in 30 Minutes: Noble Africa (NASDAQ: $NDRA ) Live Investor Webinar at 4:15 PM ET
Last chance to register. In 30 minutes, Noble Africa management goes live to discuss the Virginia Gas Project, an integrated helium and LNG platform positioned to become one of the few uppliers as global supply stays constrained. Join now to hear the story firsthand and get your questions answered live.
⚡ Why you should be in the room:
A rare ~3% average helium concentration at a project now moving into commercial production
Two revenue streams: helium for semiconductors, healthcare, aerospace and quantum computing, and LNG for South Africa’s growing gas market
Long-life production rights valid through 2042, renewable for 30 more years
A Phase 2 expansion with indicated DFC and SBSA debt support totaling up to $750M (non-binding)
Near-term milestones, including the Phase 1 nameplate ramp and initial international helium exports
Register now and join us live at 4:15 PM ET.
🔗 Register here: redchip.news/4jv6ZAq
#NDRA #NobleAfrica #Renergen #Helium #LNG #NaturalGas #NasdaqStocks #InvestorWebinar #SmallCapInvesting #EnergyStocks
Last chance to register. In 30 minutes, Noble Africa management goes live to discuss the Virginia Gas Project, an integrated helium and LNG platform positioned to become one of the few uppliers as global supply stays constrained. Join now to hear the story firsthand and get your questions answered live.
⚡ Why you should be in the room:
A rare ~3% average helium concentration at a project now moving into commercial production
Two revenue streams: helium for semiconductors, healthcare, aerospace and quantum computing, and LNG for South Africa’s growing gas market
Long-life production rights valid through 2042, renewable for 30 more years
A Phase 2 expansion with indicated DFC and SBSA debt support totaling up to $750M (non-binding)
Near-term milestones, including the Phase 1 nameplate ramp and initial international helium exports
Register now and join us live at 4:15 PM ET.
🔗 Register here: redchip.news/4jv6ZAq
#NDRA #NobleAfrica #Renergen #Helium #LNG #NaturalGas #NasdaqStocks #InvestorWebinar #SmallCapInvesting #EnergyStocks
0
0
0
180
Anixa Biosciences ($ANIX): Ovarian Cancer CAR-T Trial to Be Presented at ESMO Immuno-Oncology Congress
Dr. Robert Wenham of Moffitt Cancer Center, principal investigator of Anixa’s Phase 1 trial of lira-cel, will present the company’s CAR-T therapy for recurrent ovarian cancer on December 14 at the ESMO Immuno-Oncology & Advanced Therapies Congress in London. Anixa recently finished treating the fifth cohort at a dose 100 times higher than the first patient received, and it plans to move to a sixth cohort at 1,000 times the initial dose. No dose-limiting toxicities have been observed so far. Four patients have survived more than a year after treatment, including one beyond two years.
Full press release: redchip.news/4zbKPri
Dr. Robert Wenham of Moffitt Cancer Center, principal investigator of Anixa’s Phase 1 trial of lira-cel, will present the company’s CAR-T therapy for recurrent ovarian cancer on December 14 at the ESMO Immuno-Oncology & Advanced Therapies Congress in London. Anixa recently finished treating the fifth cohort at a dose 100 times higher than the first patient received, and it plans to move to a sixth cohort at 1,000 times the initial dose. No dose-limiting toxicities have been observed so far. Four patients have survived more than a year after treatment, including one beyond two years.
Full press release: redchip.news/4zbKPri
0
0
0
187
Owlting Group ($OWLS): CEO Darren Wang on Scaling Global Payments Platform and the Path to Profitability
In an exclusive interview with Investing.com, Owlting CEO Darren Wang called 2026 “year one” of commercialization for Harbor, the company’s stablecoin-based cross-border payments platform. Harbor’s September payment volume was about 15 times April’s, the eighth straight month of growth. Owlting passed 100 enterprise clients in October, 23 of which were actively transacting at the time of its update. Wang said most of the acceleration came after June 30, so full-year 2026 results will be the first to show it. He also set out a long-term objective of about $500 million in annual revenue from OwlPay and stablecoin-enabled services by 2030, which he described as “an objective, not a forecast.”
Learn More: redchip.news/4zsCSik
In an exclusive interview with Investing.com, Owlting CEO Darren Wang called 2026 “year one” of commercialization for Harbor, the company’s stablecoin-based cross-border payments platform. Harbor’s September payment volume was about 15 times April’s, the eighth straight month of growth. Owlting passed 100 enterprise clients in October, 23 of which were actively transacting at the time of its update. Wang said most of the acceleration came after June 30, so full-year 2026 results will be the first to show it. He also set out a long-term objective of about $500 million in annual revenue from OwlPay and stablecoin-enabled services by 2030, which he described as “an objective, not a forecast.”
Learn More: redchip.news/4zsCSik
0
0
0
177
🚨 TODAY: Noble Africa (NASDAQ: $NDRA ) Live Investor Webinar at 4:15 PM ET
The Noble Africa investor webinar is today. This afternoon, management will present the Virginia Gas Project, one of the world’s highest commercially scalable helium resources, as it moves into n a supply-constrained helium market. Bring your questions on production, expansion financing and the path to value creation.
📋 What’s on the table today:
~3% average helium concentration, well above typical conventional reservoirs at less than 0.5%
South Africa’s only onshore petroleum production right, held through 94.5%-owned Tetra4, valid through 2042 and renewable for 30 more years
Phase 1 ramping toward nameplate capacity, with Phase 2 designed to significantly expand helium and LNG output
Indicated Phase 2 debt support of up to $500M from the DFC and up to $250M from SBSA (non-binding)
A leadership team headed by Paul Mann, who built ASP Isotopes into a $1B+ Nasdaq-listed company
Register now to join the live presentation this afternoon.
🔗 Register here: redchip.news/4jv6ZAq
#NDRA #NobleAfrica #Renergen #Helium #LNG #NaturalGas #NasdaqStocks #InvestorWebinar #SmallCapInvesting #EnergyStocks
The Noble Africa investor webinar is today. This afternoon, management will present the Virginia Gas Project, one of the world’s highest commercially scalable helium resources, as it moves into n a supply-constrained helium market. Bring your questions on production, expansion financing and the path to value creation.
📋 What’s on the table today:
~3% average helium concentration, well above typical conventional reservoirs at less than 0.5%
South Africa’s only onshore petroleum production right, held through 94.5%-owned Tetra4, valid through 2042 and renewable for 30 more years
Phase 1 ramping toward nameplate capacity, with Phase 2 designed to significantly expand helium and LNG output
Indicated Phase 2 debt support of up to $500M from the DFC and up to $250M from SBSA (non-binding)
A leadership team headed by Paul Mann, who built ASP Isotopes into a $1B+ Nasdaq-listed company
Register now to join the live presentation this afternoon.
🔗 Register here: redchip.news/4jv6ZAq
#NDRA #NobleAfrica #Renergen #Helium #LNG #NaturalGas #NasdaqStocks #InvestorWebinar #SmallCapInvesting #EnergyStocks
0
0
0
236
Join Our Investor LIVE Q&A ASP Isotopes - LIVE NOW x.com/i/broadcasts/2…
0
0
0
284
⏳ Starting in 30 Minutes: ASP Isotopes (NASDAQ: $ASPI) Live Investor Webinar at 4:15 PM ET
Last chance to register. In 30 minutes, ASPI management goes live to discuss four critical-materials businesses that are maturing at the same time, in nuclear medicine, electronics, . Join now to hear the strategy firsthand and get your questions answered live.
⚡ Why you should be in the room:
Three enrichment plants operating in Pretoria, with Silicon-28 uptime up from 58% to 90%
$5.1M in Q2 2026 revenue, with LNG shipments underway and the helium plant in commissioning
A Phase 2 helium target of ~900 Mcf/day, about 13x Phase 1 nameplate capacity
QLE work on U.S. uranium conversion with Texas A&M, plus enrichment programs advancing in the U.S. and U.K.
$254.9M in cash and equivalents at June 30, 2026
Register now and join us live at 4:15 PM ET.
🔗 Register here: redchip.news/4hUxXAi
#ASPI #ASPIsotopes #Isotopes #NuclearMedicine #Helium #NuclearEnergy #CriticalMaterials #NasdaqStocks #InvestorWebinar #SmallCapInvesting
Last chance to register. In 30 minutes, ASPI management goes live to discuss four critical-materials businesses that are maturing at the same time, in nuclear medicine, electronics, . Join now to hear the strategy firsthand and get your questions answered live.
⚡ Why you should be in the room:
Three enrichment plants operating in Pretoria, with Silicon-28 uptime up from 58% to 90%
$5.1M in Q2 2026 revenue, with LNG shipments underway and the helium plant in commissioning
A Phase 2 helium target of ~900 Mcf/day, about 13x Phase 1 nameplate capacity
QLE work on U.S. uranium conversion with Texas A&M, plus enrichment programs advancing in the U.S. and U.K.
$254.9M in cash and equivalents at June 30, 2026
Register now and join us live at 4:15 PM ET.
🔗 Register here: redchip.news/4hUxXAi
#ASPI #ASPIsotopes #Isotopes #NuclearMedicine #Helium #NuclearEnergy #CriticalMaterials #NasdaqStocks #InvestorWebinar #SmallCapInvesting
0
0
0
948
🧬 Cancer claims about 10 million lives every year, and an estimated 90% of those deaths come from metastatic cancer.
TransCode Therapeutics (Nasdaq: RNAZ), whose team includes scientists from Harvard Medical School, is developing a new treatment for metastatic cancer. Its drug ble safety, tolerability and disease stabilization in a Phase 1 clinical trial and is now being tested in a Phase 2 trial in colorectal cancer.
👉 Learn more: redchip.news/4A4BYby
#RNAZ #TransCodeTherapeutics #MetastaticCancer #ColorectalCancer #Oncology #RNATherapeutics #Biotech #BiotechStocks #Nasdaq #SmallCapStocks
TransCode Therapeutics (Nasdaq: RNAZ), whose team includes scientists from Harvard Medical School, is developing a new treatment for metastatic cancer. Its drug ble safety, tolerability and disease stabilization in a Phase 1 clinical trial and is now being tested in a Phase 2 trial in colorectal cancer.
👉 Learn more: redchip.news/4A4BYby
#RNAZ #TransCodeTherapeutics #MetastaticCancer #ColorectalCancer #Oncology #RNATherapeutics #Biotech #BiotechStocks #Nasdaq #SmallCapStocks
0
0
0
154
🫁 More than 16 million Americans live with COPD, and emergency room visits account for roughly $7 billion in immediate follow-up healthcare costs.
Connect Biopharma (Nasdaq: CNTB) is developing a treatment to help close that gap. In a global Phase 2 trial, the company’s drug on versus placebo in patients returning to the hospital within four weeks. Connect is now preparing for a pivotal trial.
👉 Learn more: redchip.news/4A0Vi9u
#CNTB #ConnectBiopharma #COPD #Respiratory #Biotech #BiotechStocks #ClinicalTrials #Nasdaq #SmallCapStocks #RedChip
Connect Biopharma (Nasdaq: CNTB) is developing a treatment to help close that gap. In a global Phase 2 trial, the company’s drug on versus placebo in patients returning to the hospital within four weeks. Connect is now preparing for a pivotal trial.
👉 Learn more: redchip.news/4A0Vi9u
#CNTB #ConnectBiopharma #COPD #Respiratory #Biotech #BiotechStocks #ClinicalTrials #Nasdaq #SmallCapStocks #RedChip
0
0
0
168
⚡ The AI boom needs more power, and battery storage is becoming critical U.S. infrastructure.
Bimergen Energy (NYSE American: BESS) develops, owns and operates utility-scale battery farms. In its first full quarter on the NYSE American, the company reported revenue and net re. Bimergen is expanding its portfolio of battery farms, each eligible for up to 50% back in federal tax credits.
👉 Learn more: redchip.news/49gwsYr
#BESS #BimergenEnergy #BatteryStorage #EnergyStorage #AI #GridReliability #NYSEAmerican #EnergyStocks #SmallCapStocks #RedChip
Bimergen Energy (NYSE American: BESS) develops, owns and operates utility-scale battery farms. In its first full quarter on the NYSE American, the company reported revenue and net re. Bimergen is expanding its portfolio of battery farms, each eligible for up to 50% back in federal tax credits.
👉 Learn more: redchip.news/49gwsYr
#BESS #BimergenEnergy #BatteryStorage #EnergyStorage #AI #GridReliability #NYSEAmerican #EnergyStocks #SmallCapStocks #RedChip
0
0
0
147